SALT LAKE CITY, April 03, 2019 (GLOBE NEWSWIRE) -- Nu-Med Plus, Inc. (OTCQB: NUMD), a medical device leader developing new nitric oxide delivery technology, reports an increase in strategic partnership, physician and researcher inquiries, and licensing opportunities. The international interest follows recent media reporting on advances in precision inhaled nitric oxide technology under development by Nu-Med Plus.
The advancements include a new, smaller, and smarter inhaled nitric oxide delivery unit for clinical settings. Nu-Med Plus also recently advanced a portable inhaled nitric oxide unit designed for rapid response to trauma incidents, malaria outbreaks, and into developing countries without the infrastructure required to support traditional inhaled nitric oxide delivery systems.
“Scientists continue to research and recognize the impressive healing power of inhaled nitric oxide to help alleviate a diverse array of global health conditions from malaria to tuberculosis,” Nu-Med Plus CEO Jeff Robins stated. “It’s appropriate we’re experiencing a surge of interest from potential international partners and physicians seeking to democratize the therapeutic value of inhaled nitric oxide through Nu-Med Plus technology. As we continue to innovate and expand, we welcome further conversations with interested strategic partners.”
In the first quarter of 2019, Nu-Med Plus has cataloged interest from physicians, potential partners, and distributors in nearly ten countries around the globe.
Nu-Med Plus currently produces a next-generation inhaled nitric oxide unit, available for sale and for use in research and trials. The Utah-based medical device company is currently in the process of filing for FDA approval for three nitric oxide delivery units including a fixed hospital unit, clinical unit, and a portable unit. For more information please visit www.nu-medplus.com.
Follow Nu-Med Plus on Twitter and LinkedIn for the latest news.
Media Contact: eric@s2spr.com
About Nu-Med Plus, Inc.: Nu-Med Plus, Inc. founded in 2011, is a medical device development company created to explore medical applications of newly developed nitric oxide technologies. The strategy focuses on high growth-potential markets where there is a clearly defined need recognized by the medical community that can be addressed by Nu-Med Plus and its technical expertise. Initial research and product development has been in the delivery of inhaled nitric oxide gas for therapeutic use.
Forward-Looking Statements: Information set forth in this news release contains forward-looking statements that are based on assumptions as of the date of this news release. These statements reflect management's current estimates, beliefs, intentions and expectations. They are not guarantees of future performance. The Company cautions that all forward-looking statements are inherently uncertain, and that actual performance may be affected by a number of material factors, many of which are beyond the Company's control. Such factors include, among other things: risks and uncertainties relating to the Company's ability to complete proposed private placement financing. Accordingly, actual and future events, conditions and results may differ materially from the estimates, beliefs, intentions and expectations expressed or implied in the forward-looking information. Except as required under applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information.